# An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks

> **NCT00695305** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 83 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** rilapladib
- **DRUG:** placebo
- **OTHER:** 18F Fluorodeoxylucose (FDG)-PET

## Key facts

- **NCT ID:** NCT00695305
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2016-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00695305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00695305, "An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00695305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*